Physician profile
Cory D Thomas
NPI 1609373281
$1,988.61
in general payments reported to CMS, 2019-2025
20 companies · $589 in 2025
The $589 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.33 · 2020: $67.19 · 2021: $45.32 · 2022: $141 · 2023: $510 · 2024: $570 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625 · Education: $44.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.59 |
| Education | $44.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.65 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $283.55 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $272.66 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $230.98 | 2020-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $154.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $66.33 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.20 | 2023-2025 | Caplyta |
| Pfizer INC. | $37.53 | 2024 | |
| Lilly USA, LLC | $36.62 | 2020-2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $36.37 | 2024-2025 | Voquezna |
| Tris Pharma INC | $31.95 | 2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $28.83 | 2024-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $26.05 | 2024 | Auvelity |
| Astellas Pharma US INC | $21.68 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $20.26 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Watermark Medical, INC. | $20.14 | 2024 | |
| Medtronic, INC. | $15.89 | 2023 | Intellis Adaptivestim |
| Boston Scientific Corporation | $15.38 | 2025 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $15.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.